Cost-effectiveness of eplerenone in patients with systolic heart failure and mild symptoms
Identifieur interne : 003A80 ( Main/Exploration ); précédent : 003A79; suivant : 003A81Cost-effectiveness of eplerenone in patients with systolic heart failure and mild symptoms
Auteurs : Dawn Lee [Royaume-Uni] ; Koo Wilson [Royaume-Uni] ; Ron Akehurst [Royaume-Uni] ; Martin R. Cowie [Royaume-Uni] ; Faiez Zannad [France] ; Henry Krum [Australie] ; Dirk J. Van Veldhuisen [Pays-Bas] ; John Vincent [États-Unis] ; Bertram Pitt [États-Unis] ; John J V. Mcmurray [Royaume-Uni]Source :
- Heart [ 1355-6037 ] ; 2014.
Descripteurs français
- KwdFr :
- Analyse coût-bénéfice (), Antagonistes des récepteurs des minéralocorticoïdes (administration et posologie), Antagonistes des récepteurs des minéralocorticoïdes (économie), Coûts des médicaments (), Défaillance cardiaque systolique (physiopathologie), Défaillance cardiaque systolique (traitement médicamenteux), Défaillance cardiaque systolique (économie), Dépenses de santé (), Espagne, Fonction ventriculaire gauche, Humains, Indice de gravité médicale, Qualité de vie, Royaume-Uni, Simulation sur patients standardisés, Spironolactone (administration et posologie), Spironolactone (analogues et dérivés), Spironolactone (économie), Sujet âgé.
- MESH :
- administration et posologie : Antagonistes des récepteurs des minéralocorticoïdes, Spironolactone.
- analogues et dérivés : Spironolactone.
- physiopathologie : Défaillance cardiaque systolique.
- traitement médicamenteux : Défaillance cardiaque systolique.
- économie : Antagonistes des récepteurs des minéralocorticoïdes, Défaillance cardiaque systolique, Spironolactone.
- Analyse coût-bénéfice, Coûts des médicaments, Dépenses de santé, Espagne, Fonction ventriculaire gauche, Humains, Indice de gravité médicale, Qualité de vie, Royaume-Uni, Simulation sur patients standardisés, Sujet âgé.
English descriptors
- KwdEn :
- Aged, Cost-Benefit Analysis (statistics & numerical data), Drug Costs (statistics & numerical data), Health Expenditures (statistics & numerical data), Heart Failure, Systolic (drug therapy), Heart Failure, Systolic (economics), Heart Failure, Systolic (physiopathology), Humans, Mineralocorticoid Receptor Antagonists (administration & dosage), Mineralocorticoid Receptor Antagonists (economics), Patient Simulation, Quality of Life, Severity of Illness Index, Spain, Spironolactone (administration & dosage), Spironolactone (analogs & derivatives), Spironolactone (economics), United Kingdom, Ventricular Function, Left.
- MESH :
- chemical , administration & dosage : Mineralocorticoid Receptor Antagonists, Spironolactone.
- chemical , analogs & derivatives : Spironolactone.
- drug therapy : Heart Failure, Systolic.
- economics : Heart Failure, Systolic, Mineralocorticoid Receptor Antagonists, Spironolactone.
- physiopathology : Heart Failure, Systolic.
- statistics & numerical data : Cost-Benefit Analysis, Drug Costs, Health Expenditures.
- Aged, Humans, Patient Simulation, Quality of Life, Severity of Illness Index, Spain, United Kingdom, Ventricular Function, Left.
Abstract
In the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF), aldosterone blockade with eplerenone decreased mortality and hospitalisation in patients with mild symptoms (New York Heart Association class II) and chronic systolic heart failure (HF). The present study evaluated the cost-effectiveness of eplerenone in the treatment of these patients in the UK and Spain.
Results from the EMPHASIS-HF trial were used to develop a discrete-event simulation model estimating lifetime direct costs and effects (life years and quality-adjusted life years (QALYs) gained) of the addition of eplerenone to standard care among patients with chronic systolic HF and mild symptoms. Eplerenone plus standard care compared with standard care alone increased lifetime direct costs per patient by £4284 for the UK and €7358 for Spain, with additional quality-adjusted life expectancy of 1.22 QALYs for the UK and 1.33 QALYs for Spain. Mean lifetime costs were £3520 per QALY in the UK and €5532 per QALY in Spain. Probabilistic sensitivity analysis suggested a 100% likelihood of eplerenone being regarded as cost-effective at a willingness-to-pay threshold of £20 000 per QALY (UK) or €30 000 per QALY (Spain).
By currently accepted standards of value for money, the addition of eplerenone to optimal medical therapy for patients with chronic systolic HF and mild symptoms is likely to be cost-effective.
Url:
DOI: 10.1136/heartjnl-2014-305673
PubMed: 24993605
PubMed Central: 4215293
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Pmc, to step Corpus: 002571
- to stream Pmc, to step Curation: 002421
- to stream Pmc, to step Checkpoint: 001678
- to stream PubMed, to step Corpus: 003307
- to stream PubMed, to step Curation: 003197
- to stream PubMed, to step Checkpoint: 003197
- to stream Ncbi, to step Merge: 001B98
- to stream Ncbi, to step Curation: 001B98
- to stream Ncbi, to step Checkpoint: 001B98
- to stream Main, to step Merge: 003B26
- to stream Main, to step Curation: 003A80
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Cost-effectiveness of eplerenone in patients with systolic heart failure and mild symptoms</title><author><name sortKey="Lee, Dawn" sort="Lee, Dawn" uniqKey="Lee D" first="Dawn" last="Lee">Dawn Lee</name><affiliation wicri:level="1"><nlm:aff id="af1"><institution>BresMed</institution>,<addr-line>Sheffield</addr-line>,<country>UK</country></nlm:aff><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Wilson, Koo" sort="Wilson, Koo" uniqKey="Wilson K" first="Koo" last="Wilson">Koo Wilson</name><affiliation wicri:level="1"><nlm:aff id="af2"><institution>Health Economic and Outcomes Research, Pfizer Ltd</institution>,<addr-line>Surrey</addr-line>,<country>UK</country></nlm:aff><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Akehurst, Ron" sort="Akehurst, Ron" uniqKey="Akehurst R" first="Ron" last="Akehurst">Ron Akehurst</name><affiliation wicri:level="1"><nlm:aff id="af1"><institution>BresMed</institution>,<addr-line>Sheffield</addr-line>,<country>UK</country></nlm:aff><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Cowie, Martin R" sort="Cowie, Martin R" uniqKey="Cowie M" first="Martin R" last="Cowie">Martin R. Cowie</name><affiliation wicri:level="1"><nlm:aff id="af3"><institution>National Heart and Lung Institute, Imperial College (Royal Brompton Hospital) London</institution>,<addr-line>London</addr-line>,<country>UK</country></nlm:aff><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Zannad, Faiez" sort="Zannad, Faiez" uniqKey="Zannad F" first="Faiez" last="Zannad">Faiez Zannad</name><affiliation wicri:level="1"><nlm:aff id="af4"><addr-line>CHU and Department of Cardiology</addr-line>,<institution>Inserm, Centre d'Investigation Clinique CIC 9501 and U961, Nancy University</institution>,<addr-line>Nancy</addr-line>,<country>France</country></nlm:aff><country xml:lang="fr">France</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Krum, Henry" sort="Krum, Henry" uniqKey="Krum H" first="Henry" last="Krum">Henry Krum</name><affiliation wicri:level="1"><nlm:aff id="af5"><addr-line>Department of Epidemiology and Preventive Medicine</addr-line>,<institution>Centre of Cardiovascular Research and Education in Therapeutics, Monash University</institution>,<addr-line>Melbourne</addr-line>,<country>Australia</country></nlm:aff><country xml:lang="fr">Australie</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Van Veldhuisen, Dirk J" sort="Van Veldhuisen, Dirk J" uniqKey="Van Veldhuisen D" first="Dirk J" last="Van Veldhuisen">Dirk J. Van Veldhuisen</name><affiliation wicri:level="1"><nlm:aff id="af6"><addr-line>Department of Cardiology</addr-line>,<institution>Thorax Centre, University Medical Centre</institution>,<addr-line>Groningen</addr-line>,<country>The Netherlands</country></nlm:aff><country xml:lang="fr">Pays-Bas</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Vincent, John" sort="Vincent, John" uniqKey="Vincent J" first="John" last="Vincent">John Vincent</name><affiliation wicri:level="1"><nlm:aff id="af7"><institution>Pfizer, Inc.</institution>,<addr-line>New York</addr-line>,<country>USA</country></nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Pitt, Bertram" sort="Pitt, Bertram" uniqKey="Pitt B" first="Bertram" last="Pitt">Bertram Pitt</name><affiliation wicri:level="1"><nlm:aff id="af8"><institution>University of Michigan School of Medicine</institution>,<addr-line>Ann Arbor, Michigan</addr-line>,<country>USA</country></nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Mcmurray, John J V" sort="Mcmurray, John J V" uniqKey="Mcmurray J" first="John J V" last="Mcmurray">John J V. Mcmurray</name><affiliation wicri:level="1"><nlm:aff id="af9"><institution>The British Heart Foundation Cardiovascular Research Centre, University of Glasgow</institution>,<addr-line>Glasgow</addr-line>,<country>UK</country></nlm:aff><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">24993605</idno><idno type="pmc">4215293</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4215293</idno><idno type="RBID">PMC:4215293</idno><idno type="doi">10.1136/heartjnl-2014-305673</idno><date when="2014">2014</date><idno type="wicri:Area/Pmc/Corpus">002571</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">002571</idno><idno type="wicri:Area/Pmc/Curation">002421</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">002421</idno><idno type="wicri:Area/Pmc/Checkpoint">001678</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">001678</idno><idno type="wicri:source">PubMed</idno><idno type="wicri:Area/PubMed/Corpus">003307</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">003307</idno><idno type="wicri:Area/PubMed/Curation">003197</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">003197</idno><idno type="wicri:Area/PubMed/Checkpoint">003197</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">003197</idno><idno type="wicri:Area/Ncbi/Merge">001B98</idno><idno type="wicri:Area/Ncbi/Curation">001B98</idno><idno type="wicri:Area/Ncbi/Checkpoint">001B98</idno><idno type="wicri:doubleKey">1355-6037:2014:Lee D:cost:effectiveness:of</idno><idno type="wicri:Area/Main/Merge">003B26</idno><idno type="wicri:Area/Main/Curation">003A80</idno><idno type="wicri:Area/Main/Exploration">003A80</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Cost-effectiveness of eplerenone in patients with systolic heart failure and mild symptoms</title><author><name sortKey="Lee, Dawn" sort="Lee, Dawn" uniqKey="Lee D" first="Dawn" last="Lee">Dawn Lee</name><affiliation wicri:level="1"><nlm:aff id="af1"><institution>BresMed</institution>,<addr-line>Sheffield</addr-line>,<country>UK</country></nlm:aff><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Wilson, Koo" sort="Wilson, Koo" uniqKey="Wilson K" first="Koo" last="Wilson">Koo Wilson</name><affiliation wicri:level="1"><nlm:aff id="af2"><institution>Health Economic and Outcomes Research, Pfizer Ltd</institution>,<addr-line>Surrey</addr-line>,<country>UK</country></nlm:aff><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Akehurst, Ron" sort="Akehurst, Ron" uniqKey="Akehurst R" first="Ron" last="Akehurst">Ron Akehurst</name><affiliation wicri:level="1"><nlm:aff id="af1"><institution>BresMed</institution>,<addr-line>Sheffield</addr-line>,<country>UK</country></nlm:aff><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Cowie, Martin R" sort="Cowie, Martin R" uniqKey="Cowie M" first="Martin R" last="Cowie">Martin R. Cowie</name><affiliation wicri:level="1"><nlm:aff id="af3"><institution>National Heart and Lung Institute, Imperial College (Royal Brompton Hospital) London</institution>,<addr-line>London</addr-line>,<country>UK</country></nlm:aff><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Zannad, Faiez" sort="Zannad, Faiez" uniqKey="Zannad F" first="Faiez" last="Zannad">Faiez Zannad</name><affiliation wicri:level="1"><nlm:aff id="af4"><addr-line>CHU and Department of Cardiology</addr-line>,<institution>Inserm, Centre d'Investigation Clinique CIC 9501 and U961, Nancy University</institution>,<addr-line>Nancy</addr-line>,<country>France</country></nlm:aff><country xml:lang="fr">France</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Krum, Henry" sort="Krum, Henry" uniqKey="Krum H" first="Henry" last="Krum">Henry Krum</name><affiliation wicri:level="1"><nlm:aff id="af5"><addr-line>Department of Epidemiology and Preventive Medicine</addr-line>,<institution>Centre of Cardiovascular Research and Education in Therapeutics, Monash University</institution>,<addr-line>Melbourne</addr-line>,<country>Australia</country></nlm:aff><country xml:lang="fr">Australie</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Van Veldhuisen, Dirk J" sort="Van Veldhuisen, Dirk J" uniqKey="Van Veldhuisen D" first="Dirk J" last="Van Veldhuisen">Dirk J. Van Veldhuisen</name><affiliation wicri:level="1"><nlm:aff id="af6"><addr-line>Department of Cardiology</addr-line>,<institution>Thorax Centre, University Medical Centre</institution>,<addr-line>Groningen</addr-line>,<country>The Netherlands</country></nlm:aff><country xml:lang="fr">Pays-Bas</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Vincent, John" sort="Vincent, John" uniqKey="Vincent J" first="John" last="Vincent">John Vincent</name><affiliation wicri:level="1"><nlm:aff id="af7"><institution>Pfizer, Inc.</institution>,<addr-line>New York</addr-line>,<country>USA</country></nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Pitt, Bertram" sort="Pitt, Bertram" uniqKey="Pitt B" first="Bertram" last="Pitt">Bertram Pitt</name><affiliation wicri:level="1"><nlm:aff id="af8"><institution>University of Michigan School of Medicine</institution>,<addr-line>Ann Arbor, Michigan</addr-line>,<country>USA</country></nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Mcmurray, John J V" sort="Mcmurray, John J V" uniqKey="Mcmurray J" first="John J V" last="Mcmurray">John J V. Mcmurray</name><affiliation wicri:level="1"><nlm:aff id="af9"><institution>The British Heart Foundation Cardiovascular Research Centre, University of Glasgow</institution>,<addr-line>Glasgow</addr-line>,<country>UK</country></nlm:aff><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author></analytic><series><title level="j">Heart</title><idno type="ISSN">1355-6037</idno><idno type="eISSN">1468-201X</idno><imprint><date when="2014">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Cost-Benefit Analysis (statistics & numerical data)</term><term>Drug Costs (statistics & numerical data)</term><term>Health Expenditures (statistics & numerical data)</term><term>Heart Failure, Systolic (drug therapy)</term><term>Heart Failure, Systolic (economics)</term><term>Heart Failure, Systolic (physiopathology)</term><term>Humans</term><term>Mineralocorticoid Receptor Antagonists (administration & dosage)</term><term>Mineralocorticoid Receptor Antagonists (economics)</term><term>Patient Simulation</term><term>Quality of Life</term><term>Severity of Illness Index</term><term>Spain</term><term>Spironolactone (administration & dosage)</term><term>Spironolactone (analogs & derivatives)</term><term>Spironolactone (economics)</term><term>United Kingdom</term><term>Ventricular Function, Left</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Analyse coût-bénéfice ()</term><term>Antagonistes des récepteurs des minéralocorticoïdes (administration et posologie)</term><term>Antagonistes des récepteurs des minéralocorticoïdes (économie)</term><term>Coûts des médicaments ()</term><term>Défaillance cardiaque systolique (physiopathologie)</term><term>Défaillance cardiaque systolique (traitement médicamenteux)</term><term>Défaillance cardiaque systolique (économie)</term><term>Dépenses de santé ()</term><term>Espagne</term><term>Fonction ventriculaire gauche</term><term>Humains</term><term>Indice de gravité médicale</term><term>Qualité de vie</term><term>Royaume-Uni</term><term>Simulation sur patients standardisés</term><term>Spironolactone (administration et posologie)</term><term>Spironolactone (analogues et dérivés)</term><term>Spironolactone (économie)</term><term>Sujet âgé</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Mineralocorticoid Receptor Antagonists</term><term>Spironolactone</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Spironolactone</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Antagonistes des récepteurs des minéralocorticoïdes</term><term>Spironolactone</term></keywords><keywords scheme="MESH" qualifier="analogues et dérivés" xml:lang="fr"><term>Spironolactone</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Heart Failure, Systolic</term></keywords><keywords scheme="MESH" qualifier="economics" xml:lang="en"><term>Heart Failure, Systolic</term><term>Mineralocorticoid Receptor Antagonists</term><term>Spironolactone</term></keywords><keywords scheme="MESH" qualifier="physiopathologie" xml:lang="fr"><term>Défaillance cardiaque systolique</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Heart Failure, Systolic</term></keywords><keywords scheme="MESH" qualifier="statistics & numerical data" xml:lang="en"><term>Cost-Benefit Analysis</term><term>Drug Costs</term><term>Health Expenditures</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Défaillance cardiaque systolique</term></keywords><keywords scheme="MESH" qualifier="économie" xml:lang="fr"><term>Antagonistes des récepteurs des minéralocorticoïdes</term><term>Défaillance cardiaque systolique</term><term>Spironolactone</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Humans</term><term>Patient Simulation</term><term>Quality of Life</term><term>Severity of Illness Index</term><term>Spain</term><term>United Kingdom</term><term>Ventricular Function, Left</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Analyse coût-bénéfice</term><term>Coûts des médicaments</term><term>Dépenses de santé</term><term>Espagne</term><term>Fonction ventriculaire gauche</term><term>Humains</term><term>Indice de gravité médicale</term><term>Qualité de vie</term><term>Royaume-Uni</term><term>Simulation sur patients standardisés</term><term>Sujet âgé</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><sec><title>Aim</title><p>In the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF), aldosterone blockade with eplerenone decreased mortality and hospitalisation in patients with mild symptoms (New York Heart Association class II) and chronic systolic heart failure (HF). The present study evaluated the cost-effectiveness of eplerenone in the treatment of these patients in the UK and Spain.</p></sec><sec><title>Methods and results</title><p>Results from the EMPHASIS-HF trial were used to develop a discrete-event simulation model estimating lifetime direct costs and effects (life years and quality-adjusted life years (QALYs) gained) of the addition of eplerenone to standard care among patients with chronic systolic HF and mild symptoms. Eplerenone plus standard care compared with standard care alone increased lifetime direct costs per patient by £4284 for the UK and €7358 for Spain, with additional quality-adjusted life expectancy of 1.22 QALYs for the UK and 1.33 QALYs for Spain. Mean lifetime costs were £3520 per QALY in the UK and €5532 per QALY in Spain. Probabilistic sensitivity analysis suggested a 100% likelihood of eplerenone being regarded as cost-effective at a willingness-to-pay threshold of £20 000 per QALY (UK) or €30 000 per QALY (Spain).</p></sec><sec><title>Conclusions</title><p>By currently accepted standards of value for money, the addition of eplerenone to optimal medical therapy for patients with chronic systolic HF and mild symptoms is likely to be cost-effective.</p></sec></div></front><back><div1 type="bibliography"><listBibl><biblStruct></biblStruct><biblStruct><analytic><author><name sortKey="Mosterd, A" uniqKey="Mosterd A">A Mosterd</name></author><author><name sortKey="Hoes, Aw" uniqKey="Hoes A">AW Hoes</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Cowie, Mr" uniqKey="Cowie M">MR Cowie</name></author><author><name sortKey="Wood, Da" uniqKey="Wood D">DA Wood</name></author><author><name sortKey="Coats, Ajs" uniqKey="Coats A">AJS Coats</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Stewart, S" uniqKey="Stewart S">S Stewart</name></author><author><name sortKey="Macintyre, K" uniqKey="Macintyre K">K MacIntyre</name></author><author><name sortKey="Hole, Dj" uniqKey="Hole D">DJ Hole</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Mcmurray, Jjv" uniqKey="Mcmurray J">JJV McMurray</name></author><author><name sortKey="Adamopoulos, S" uniqKey="Adamopoulos S">S Adamopoulos</name></author><author><name sortKey="Anker, Sd" uniqKey="Anker S">SD Anker</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Pitt, B" uniqKey="Pitt B">B Pitt</name></author><author><name sortKey="Zannad, F" uniqKey="Zannad F">F Zannad</name></author><author><name sortKey="Remme, Wj" uniqKey="Remme W">WJ Remme</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Zannad, F" uniqKey="Zannad F">F Zannad</name></author><author><name sortKey="Mcmurray, Jj" uniqKey="Mcmurray J">JJ McMurray</name></author><author><name sortKey="Krum, H" uniqKey="Krum H">H Krum</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Pitt, B" uniqKey="Pitt B">B Pitt</name></author><author><name sortKey="Remme, W" uniqKey="Remme W">W Remme</name></author><author><name sortKey="Zannad, F" uniqKey="Zannad F">F Zannad</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Caro, Jj" uniqKey="Caro J">JJ Caro</name></author><author><name sortKey="Moller, J" uniqKey="Moller J">J Möller</name></author><author><name sortKey="Getsios, D" uniqKey="Getsios D">D Getsios</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Preiss, D" uniqKey="Preiss D">D Preiss</name></author><author><name sortKey="Van Veldhuisen, Dj" uniqKey="Van Veldhuisen D">DJ van Veldhuisen</name></author><author><name sortKey="Sattar, N" uniqKey="Sattar N">N Sattar</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Fox, M" uniqKey="Fox M">M Fox</name></author><author><name sortKey="Mealing, S" uniqKey="Mealing S">S Mealing</name></author><author><name sortKey="Anderson, R" uniqKey="Anderson R">R Anderson</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Harrell, F" uniqKey="Harrell F">F Harrell</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Rogers, Jk" uniqKey="Rogers J">JK Rogers</name></author><author><name sortKey="Mcmurray, Jj" uniqKey="Mcmurray J">JJ McMurray</name></author><author><name sortKey="Pocock, Sj" uniqKey="Pocock S">SJ Pocock</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Gohler, A" uniqKey="Gohler A">A Göhler</name></author><author><name sortKey="Geisler, Bp" uniqKey="Geisler B">BP Geisler</name></author><author><name sortKey="Manne, Jm" uniqKey="Manne J">JM Manne</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Hart, W" uniqKey="Hart W">W Hart</name></author><author><name sortKey="Rhodes, G" uniqKey="Rhodes G">G Rhodes</name></author><author><name sortKey="Mcmurray, J" uniqKey="Mcmurray J">J McMurray</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Mcmurray, Jj" uniqKey="Mcmurray J">JJ McMurray</name></author><author><name sortKey="Andersson, Fl" uniqKey="Andersson F">FL Andersson</name></author><author><name sortKey="Stewart, S" uniqKey="Stewart S">S Stewart</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Stewart, S" uniqKey="Stewart S">S Stewart</name></author><author><name sortKey="Mcmurray, Jj" uniqKey="Mcmurray J">JJ McMurray</name></author><author><name sortKey="Hebborn, A" uniqKey="Hebborn A">A Hebborn</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Bacquet, P" uniqKey="Bacquet P">P Bacquet</name></author><author><name sortKey="Levy, E" uniqKey="Levy E">E Levy</name></author><author><name sortKey="Mcguire, A" uniqKey="Mcguire A">A McGuire</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Sullivan, Pw" uniqKey="Sullivan P">PW Sullivan</name></author><author><name sortKey="Slejko, Jf" uniqKey="Slejko J">JF Slejko</name></author><author><name sortKey="Sculpher, Mj" uniqKey="Sculpher M">MJ Sculpher</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Bassler, D" uniqKey="Bassler D">D Bassler</name></author><author><name sortKey="Briel, M" uniqKey="Briel M">M Briel</name></author><author><name sortKey="Montori, Vm" uniqKey="Montori V">VM Montori</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Stewart, S" uniqKey="Stewart S">S Stewart</name></author><author><name sortKey="Jenkins, A" uniqKey="Jenkins A">A Jenkins</name></author><author><name sortKey="Buchan, S" uniqKey="Buchan S">S Buchan</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Stewart, S" uniqKey="Stewart S">S Stewart</name></author><author><name sortKey="Blue, L" uniqKey="Blue L">L Blue</name></author><author><name sortKey="Walker, A" uniqKey="Walker A">A Walker</name></author></analytic></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct><analytic><author><name sortKey="Curtis, L" uniqKey="Curtis L">L Curtis</name></author></analytic></biblStruct><biblStruct></biblStruct><biblStruct><analytic><author><name sortKey="Berg, J" uniqKey="Berg J">J Berg</name></author><author><name sortKey="Lindgren, P" uniqKey="Lindgren P">P Lindgren</name></author><author><name sortKey="Nieuwlaat, R" uniqKey="Nieuwlaat R">R Nieuwlaat</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Mowatt, G" uniqKey="Mowatt G">G Mowatt</name></author><author><name sortKey="Vale, L" uniqKey="Vale L">L Vale</name></author><author><name sortKey="Perez, J" uniqKey="Perez J">J Perez</name></author></analytic></biblStruct></listBibl></div1></back></TEI><affiliations><list><country><li>Australie</li><li>France</li><li>Pays-Bas</li><li>Royaume-Uni</li><li>États-Unis</li></country></list><tree><country name="Royaume-Uni"><noRegion><name sortKey="Lee, Dawn" sort="Lee, Dawn" uniqKey="Lee D" first="Dawn" last="Lee">Dawn Lee</name></noRegion><name sortKey="Akehurst, Ron" sort="Akehurst, Ron" uniqKey="Akehurst R" first="Ron" last="Akehurst">Ron Akehurst</name><name sortKey="Cowie, Martin R" sort="Cowie, Martin R" uniqKey="Cowie M" first="Martin R" last="Cowie">Martin R. Cowie</name><name sortKey="Mcmurray, John J V" sort="Mcmurray, John J V" uniqKey="Mcmurray J" first="John J V" last="Mcmurray">John J V. Mcmurray</name><name sortKey="Wilson, Koo" sort="Wilson, Koo" uniqKey="Wilson K" first="Koo" last="Wilson">Koo Wilson</name></country><country name="France"><noRegion><name sortKey="Zannad, Faiez" sort="Zannad, Faiez" uniqKey="Zannad F" first="Faiez" last="Zannad">Faiez Zannad</name></noRegion></country><country name="Australie"><noRegion><name sortKey="Krum, Henry" sort="Krum, Henry" uniqKey="Krum H" first="Henry" last="Krum">Henry Krum</name></noRegion></country><country name="Pays-Bas"><noRegion><name sortKey="Van Veldhuisen, Dirk J" sort="Van Veldhuisen, Dirk J" uniqKey="Van Veldhuisen D" first="Dirk J" last="Van Veldhuisen">Dirk J. Van Veldhuisen</name></noRegion></country><country name="États-Unis"><noRegion><name sortKey="Vincent, John" sort="Vincent, John" uniqKey="Vincent J" first="John" last="Vincent">John Vincent</name></noRegion><name sortKey="Pitt, Bertram" sort="Pitt, Bertram" uniqKey="Pitt B" first="Bertram" last="Pitt">Bertram Pitt</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003A80 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003A80 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= PMC:4215293
|texte= Cost-effectiveness of eplerenone in patients with systolic heart failure and mild symptoms
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:24993605" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |